標(biāo)題：Research Grade Bebtelovimab 對照抗體,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/7162.html

名稱：Research Grade Bebtelovimab對照抗體

別名：Bebtelovimab對照抗體，LY-CoV1404, LY3853113, SARS-like Coronaviruses

貨號：DVV00319

適用物種：SARS-CoV-2 (2019-nCoV)

寄主物種：Human

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG1, lambda2

應(yīng)用：Research Grade Biosimilar

UniProt：P0DTC2-2

靶點(diǎn)：Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD

用途范圍：僅用于科研

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Bebtelovimab. PMID: 35230755

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. PMID: 33972947

Bebtelovimab in the Real World: Promise and Fulfillment. PMID: 36124710

Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest. PMID: 36003828

COVID-19 update: Bebtelovimab EUA withdrawn. PMID: 36651898

COVID-19 update: Resistance to bebtelovimab. PMID: 36397193

An EUA for bebtelovimab for treatment of COVID-19. PMID: 35294426

Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System. PMID: 36438619

Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. PMID: 35939386

Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants. PMID: 36756927

SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis. PMID: 37701439

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era. PMID: 36324319

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5. PMID: 37072054

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. PMID: 35714668

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic. PMID: 36174596

Serious Infusion Reactions in Two Adolescents Receiving Bebtelovimab. PMID: 36476524

Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. PMID: 35848574

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. PMID: 36124696

Effectiveness of Bebtelovimab Against Hospitalization and Death From the Omicron BA.4/BA.5 and BQ.1/BQ.1.1 Subvariants. PMID: 37414096

Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19. PMID: 37313067

The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis. PMID: 37085048

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch. PMID: 36213724

Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID-19 infection at an ambulatory cancer center. PMID: 38191852

Federal Government Buys Thousands of Bebtelovimab Doses. PMID: 35315904

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants. PMID: 36992294

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era. PMID: 37115780

Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. PMID: 37085220

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab. PMID: 35863364

COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge. PMID: 36228295

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. PMID: 36077159

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. PMID: 36788246

Current Effective Therapeutics in Management of COVID-19. PMID: 35807123

Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review. PMID: 37129306

Outpatient Management of COVID-19: A Primer for the Dermatologist. PMID: 36035078

Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review. PMID: 37719798

Update on COVID-19 Therapy in Pediatric Age. PMID: 36558963

Antibody evasion properties of SARS-CoV-2 Omicron sublineages. PMID: 35240676

Colitis After SARS-CoV-2 Infection. PMID: 35928392

Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron. PMID: 37708028

Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study. PMID: 37011399

Therapeutic monoclonal antibodies for COVID-19 management: an update. PMID: 35604379